Efficacy and Tolerability of Budesonide Aqueous Nasal Spray Treatment in Patients With Nasal Polyps

Jankowski, R.; Schrewelius, Camilla; Bonfils, P.; Saban, Yves; Gilain, Laurent; Prades, Jean-Michel; Strunski, V.

doi:10.1001/archotol.127.4.447

Cited by 67 publications

(63 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study authors were contacted via e-mail for raw data in cases of missing data. [17][18][19][20][21][22][23][24][25][26][27][28][29][30] The analyses were based on intention to treat. For missing standard deviations, either 95% CIs, 23,31,32 standard error.…”

Section: Discussionmentioning

confidence: 99%

Sinus Surgery and Delivery Method Influence the Effectiveness of Topical Corticosteroids for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis

Snidvongs

Kalish

Sacks

et al. 2013

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Sinus Surgery and Delivery Method Influence the Effectiveness of Topical Corticosteroids for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis

Snidvongs

Kalish

Sacks

et al. 2013

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

“…[102][103][104][105][106][107] In 183 patients with moderate-sized nasal polyps causing clinically significant symptoms, budesonide aqueous nasal spray at a dose of 128 µg once or twice daily, or 256 µg once daily for eight weeks significantly reduced polyp size (p<0.01) and improved peak nasal inspiratory flow (p<0.001) compared with placebo. 106 Combined and individual symptom scores (blocked nose, runny nose, and sneezing) and sense of smell also improved significantly in all budesonide-treated groups. These findings were confirmed by results of a similarly designed 8-week trial comparing budesonide 140 µg once or twice daily, 280 µg once daily, or placebo in 157 patients with symptomatic bilateral nasal polyposis.…”

Section: Acute Rhinosinusitis and Nasal Polyposis: Association With Amentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

“…According to the previously described method, we excluded patients who did not take drugs regularly or correctly when screening subjects belonging to the steroid-sensitive and steroid-resistant groups, to improve the objectivity of curative effects of intranasal steroid [6]. Fluorescent quantitative PCR is a relatively accurate measurement method, which can directly quantify the products by detecting fluorescent signals because the production of fluorescent signals corresponds to the amplified products one to one.…”

Section: Discussionmentioning

confidence: 99%

“…However, the mechanism of negative effects of CS-β requires further investigation. In this study, we assigned patients to the steroid-resistant group based on evaluation methods proposed by Jankowski et al [6]; however, other factors may affect AR treatment response, such as CS tolerance, competition between intranasal drug solutions or distribution with mucociliary clearance in the nasal cavity [20]. Thus, further clinical studies are needed.…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of the High Expression of Corticosteroid Receptor-Beta mRNA in the Nasal Mucosa of Steroid-Resistant Patients with Allergic Rhinitis

Luo

Zhang²,

Yu³

et al. 2014

ORL

View full text Add to dashboard Cite

Purpose: This study investigated clinical values of corticosteroid (CS) receptor α and β in the nasal mucosa of patients with allergic rhinitis (AR) by determining CS receptor α and β mRNA expression following steroid treatment. Procedures: Among 120 outpatients, 65 had persistent AR, including 36 being sensitive to steroid treatment (steroid-sensitive group) and 29 being resistant to steroid treatment (steroid-resistant group). In addition, 30 patients with deflection of the nasal septum alone, which was corrected by surgery, were recruited as controls. Fluorescent quantitative reverse transcription-PCR was used to quantify CS receptor α and β mRNA expression in the nasal mucosa of patients. Results: Results showed that CS receptor β mRNA expression in the nasal mucosa was significantly higher in the steroid-resistant group [(5.62 ± 1.28) × 102 copies/µg] compared with the steroid-sensitive [(4.62 ± 0.48) × 102 copies/µg, t = -6.67, p < 0.01] and control [(5.32 ± 0.55) × 102 copies/µg, t = -8.29, p < 0.01] groups. There were significant differences in the mRNA expression ratio of CS receptor α to β between the steroid-sensitive (658.32 ± 65.16) and steroid-resistant (525.70 ± 68.10) groups (t = 10.16, p < 0.01). Conclusion: A high level of CS receptor β mRNA but a low level of CS receptor α mRNA expression in patients with steroid-resistant AR indicates steroid resistance. CS receptor β plays a role in evaluating the effects of steroid therapy for AR.

show abstract

Efficacy and Tolerability of Budesonide Aqueous Nasal Spray Treatment in Patients With Nasal Polyps

Abstract: Doses of budesonide aqueous nasal spray, 128 microg once daily, were found to be effective in the treatment of nasal polyps, and doses of budesonide aqueous nasal spray, 256 microg once daily, did not show any significant additional efficacy.

Cited by 67 publications

References 13 publications

Sinus Surgery and Delivery Method Influence the Effectiveness of Topical Corticosteroids for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis

Sinus Surgery and Delivery Method Influence the Effectiveness of Topical Corticosteroids for Chronic Rhinosinusitis: Systematic Review and Meta-Analysis

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Clinical Value of the High Expression of Corticosteroid Receptor-Beta mRNA in the Nasal Mucosa of Steroid-Resistant Patients with Allergic Rhinitis

Contact Info

Product

Resources

About